The picture is one of systems-level pharmacology rather than single-target agonism
This safety profile, demonstrated across multiple clinical trials for metabolic applications, may make it suitable for long-term joint support applications without the risks associated with traditional GH therapy
What would change my view A well-designed randomized controlled trial directly comparing at-home microinfusion at 0.5mm with a multi-peptide serum against topical application of the same serum without the device, with VISIA or similar objective imaging at 12 and 24 weeks, would be the cleanest piece of evidence the category currently lacks
A: Both work through the same principle of direct nutrient delivery, so the better option depends on the formula, your skin goals, and how you prefer to receive treatment
At the 5mg/ml concentration, 100 units is straightforward but uses the entire syringe capacity